Methods of treating inflammatory skin disorders

ABSTRACT

A method for treating, remedying, or preventing inflammatory skin disorders by administering a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation. The method for treating, remedying, or preventing an inflammatory skin disorder by administering topically and to the prepsoriatic rim a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. Pat. Application No.16/888,709, filed May 30, 2020, which is a continuation of U.S. Pat.Application No. 15/355,723, filed Nov. 18, 2016, now U.S. Pat. No.10,668,132, the contents of which are incorporated by reference in theirentirety.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted electronically in XML format and is hereby incorporated byreference in its entirety. Said XML copy, created on Oct. 19, 2022, isnamed 54955-710 _304SL.xml and is 1,058 bytes in size

FIELD OF THE INVENTION

This invention relates to compositions and compounds that are CGRPantagonists, or reduces its activity for use in particular for treatingand or preventing psoriasis.

Psoriasis is a chronic skin disorder that afflicts about 2 percent ofthe population. The disease is associated with the rapid turnover ofskin cells (hyperproliferation) accompanied by a loss of differentiationso that silvery white scales form on the surface of the skin.Additionally, the capillaries become tortuous and dilated and aninflammatory reaction occurs, so that the skin reddens. The elevatedsilvery white scales on a contrasting red background produce theunsightly lesions characteristic of psoriasis. Psoriasis most commonlyappears on the scalp, knees, elbows, hands and feet, but can affect anypart of the skin. The cause of the disease is unknown, though it isbelieved to have a genetic component, and it has been suggested to be aT-cell mediated autoimmune skin disorder. There have been many attemptsto treat the disease, and several topical and systemic treatments forpsoriasis which inhibit cell division have been tried, with limitedsuccess in clearing the skin for short periods of time. Yet, the reasonwhy these treatments work is not yet clearly understood. Treatmentswhich have been suggested in the art appear to be symptomatic andpalliative. Lesions may disappear spontaneously or as a result of thetherapy, but recurrences are likely.

The present invention is directed to methods of treatment of psoriasisbased on observations and new findings that strongly indicate thatpsoriasis is a disease of the nervous system, and that the neuropeptidecalcitonin gene-related peptide (CGRP) is a major mediator of thedisease.

CGRP is a 37 amino acid polypeptide that is stored and released fromnerve terminals in both the central nervous system and the peripheralnervous system. CGRP has been detected in nerves innervating the heart,peripheral and cerebral blood vessels, and kidneys byimmunohistochemical (such as ELISA) and radioimmunoassay methods. CGRPhas been shown to mediate its biological response by binding to specificcell surface receptors that have been identified in a variety oftissues.

CGRP also is a very important neuropeptide (NP) in wound healing and isthe first NP that is released during that process. CGR-P is a verystrong vasodilator and is a strong inhibitor of delayed typehypersensitivity (DTH). CGRP is known to play a role in the regulationof hair growth, and can stimulate the proliferation of keratinocytes.

Tryptase is a protease enzyme that cleaves CGRP and reduces itsactivity. CGRP 8-37 is an endogen peptide that is made from CGRP byspecific cleavage by tryptase. CGRP 8-37 is a high affinity antagonistfor the CGRP receptor. It is thought that this antagonist is an endogencompound used by the body for the down-regulating neural signals(negative feedback control).

More capillary loops are seen in papillary dermis in psoriasis thanhealthy skin. These vessels in the horizontal plexus are an integralcomponent of the lesions in psoriasis vulgaris and pustular psoriasis ofvon Zunibusch. The capillary loops in the papillary dermis of psoriaticlesions become. dilated and tortuous before epidermal hyperplasia hasbeen detected morphologically. Based upon light microscopic studies ofdeveloping psoriatic lesions, Pinkus and Mehthregan have concluded thatinitial vasodilatation accompanied by an exudation of inflammatory cellsand serum in the papilla is the initiating event in psoriasis (Pinkus,Mehthregan J. Invest. Dermatol. 1 966 Jan;46(1):109-16).

Several investigators, who studied developing 1-mm psoriatic lesions,found an upward proliferation of the dermal papillae at edges ofpsoriatic lesions. They believed this enlargement was one of theinitiating events, although the stimulus was unknown (see e.g. BraunFalco and Cristophers, Arch. Dermatol Forsch. 1974;251(2):95-110).Braverman et al. found based upon the pattern by which the loops inpsoriasis vulgaris return to normal and the pattern of vascular labelingin Zumbuch disease, the mechanism how the capillary loop develops. Theendothelial cells in the extrapapillary venous limb enlarges and thearterial part becomes shorter as the papilla enlarges. The venous partbecomes fenestrated (Braverman, I.M., in Psoriasis 3rd ed. (pp.399-407), 1998, ed.: Roenikg, H.H.; Maibach H.I., Marcel Dekker Inc.,NY).

An analogous phenomenon develops in the microvasculature of rat skinduring the hair growth cycle (Sholley and Cotran Am. J. Anat. 1976 Oct;147(2):243-54). The capillary network around actively growing follicle(anagen phase) increases in size by endothelial cell proliferation.Virtually all the endothelial cells are supplied by the capillaries. Inhuman skin, both glabrous (Braverman, I.M. supra) and scalp (McLeod,W.A.; J. Invest. Dermatol., 1970, 55(5), 354-7), the capillary networkaround the hair follicles has a venous ultrastructure: bridgefenestration and a laminated basal membrane. When the rat hair follicleenters catagen, the vascular network is greatly reduced in size, partlythrough loss and partly through collapse.

The growth cycle of hair is a well-known phenomenon. Hair follicles growin repeated cycles. One cycle can be broken down into three phases:anagen (growth phase), catagen (transitional phase), and telogen(resting phase). In any one time, about 85% of hairs of all hairs are inanagen phase. At the end of anagen phase the hairs enter into catagenphase, which lasts about one or two weeks. The telogen phase follows thecatagen phase and normally lasts about 5-6 weeks. Approximately 10-15%of all hairs are in this phase at any one time. The reason why such arelatively large fraction of hairs are in telogen phase can be that theyare thus prepared to act in keratinocyte proliferation in case of woundhealing. To do so, a common factor will have to act in the regulation ofearly wound healing and regulation of the hair growth cycle. CGRPprovides this role.

It is here postulated that CGRP turns hair follicles to proliferativephase to bring stem cell keratinocytes to the surface to participate inkeratinocyte proliferation of the epidermis when the skin is healing.The keratinocytes come from the outer root sheath or the papilla dermisof the hair follicle. This is further supported by the fact thatneuropeptides are thought to play a major role in regulating hair growth(see, e.g., J. Invest. Dermatol. Symp. Proc. 1997; 2(1), 61-68).

Studies have shown that the dermal papilla is probably the primarytarget in alopecia areata (AA). This is why CGRP is a common actor onthese stem cells both in AA and psoriasis. Psoriatic keratinocytes whichare all of a specific subtype are thought to come from the stem cellslocated in the hair follicle.

As described in the accompanying Example 4, it has been observed thatpsoriasis frequently appears with a hexagonal structure in the skin,that is, the psoriasis lesions appear as hexagons, both as singlyisolated and also interconnected in a honeycomb pattern. It ispostulated herein that these hexagons may represent neurological unitsof sensory innervation. This may indicate that one or more neuralsegments or units are involved when psoriasis lesions develop. There isa similarity in distribution and shape of Herpes Zoster (viral nerveinfection) lesions (see Example 5). This further supports the theorythat the pattern of psoriasis is indicative to neural origin of thedisease.

Six-corner (hexagonal) shape lesions in psoriasis are for the most partof fixed size for a given part of the body, as shown in Example 4. Theexact structure of the nerve innervations in the skin has never beendescribed in detail but the hexagonal shape is widely seen in nature asin the bee cube and in the portal system of the liver.

The most common localizations of psoriasis lesions can be explainedbased on neural origin of psoriasis. Striking symmetry of the lesions iscommon and lesions are located in areas that are known or likely nerveoverlap areas, as e.g. the navel, lower back, temporal scalp region,elbows and knees. On the scalp and on the sacral area are very likelyembryonic parts of the neural crest that are the last to close in thefetal development of the skin. This is further supported by the factthat aplasia cutis absence of skin most often is located on the scalp inthe right temporal area, and spina bifida is located in the lumbosacralarea. Location of psoriasis in the scalp, lumbosacral area, elbows andknees are particularly interesting. If one thinks of an animal on fourlegs, these parts are the rear, the front, and the prominent part of theextremities. Psoriasis lesions often appear at the same spots on theskin repeatedly, i.e. with a memory effect. This is the same as oftenseen in herpes simplex infections (viral nerve infection in peripheralskin). I have seen clinical case of a psoriasis patient that hadpsoriasis lesions distributed along a dermatome (nerve innervationarea). The same pattern is seen in Herpes Zoster infection (viral nerveinfection).

It has been observed by the Inventor that psoriasis lesions can bedistributed over nerve innervation area on the hands.

Individual keratinocytes in the skin also have hexagonal form. Psoriatickeratinocytes express high levels of NGF (nerve growth factor) whichstimulates growth of nerves in the skin. (Acta Derm Ven March1998.84-86) Reports of psoriasis getting better after sensory nervedamage is further clinical evidence supporting the role of nerves in thepathogenesis of psoriasis. (J. of the Am. Acad. Dermatol. 28, 3,488-489; Int. J. Dermatol. 1990, 9:418-20).

Several other observations support the thesis underlying the currentInvention, that psoriasis is a neurogenerative disease, though this hasnot been clearly indicated in the prior art. Psoriasis developed contralateral to hemi paresis following cerebrovascular accident. (Int. J:Dermatol. 3 (8): 598-9 1993 Aug. ). Patients with leprosy havedestruction of peripheral nerves. It has also been noted that leprosypatients have decreased incidence of psoriasis. CGRP increases withneural trauma. CGRP 8-37 (a CGRP antagonist, described below) blocks itsincrease (Am. J. Physiol. 268 (2pt2) H584-90 1995 Feb). Prompt remissionof a psoriatic plaque has been reported following cutaneous nervesectioning. (Dewing, S.B. Arch Dermatol 104:220-221 1971).

In an investigation by means of fluorescein angiography, the retinalpigment epithelial cells in pigmented rabbits were observed. A hexagonalpattern was regularly seen away from the medullar rays. The patternbecame larger at the periphery than in the posterior pole. Theseangiographic findings closely matched those of retinal pigmentepithelial cells as seen by scanning electron microscopy and fluoresceinlight microscopy in sizes and shapes. This pattern in the sensoryinnervation in the retina is similar to that described herein for neuralunits of the skin. The hexagonal pattern in the skin becomes larger inthe periphery, i.e. on the extremities. (lida et al. Nippon-Ganka GakkaiZasshi 1991, 95(5):421-7)

CGRP and Substance P (SP) in psoriasis and possible coordination innerve function.

Farber et al. first proposed in 1986 a possible role for neuropeptidesin the pathogenesis of psoriasis (see review in Raychaudhuri, P.,Farber, E.M. in Psoriasis 3rd ed. (pp. 383-391), 1998, ed.: Roenikg,H.H.; Maibach H.I., Marcel Dekker Inc., NY. Researchers have focused inparticular on SP, and some SP antagonists have been suggested fortreating psoriasis, e.g. Somatostatin and Spantide (Farber et al.,supra). Both SP and CGRP are often located in the same nerves in theskin. SP and CGRP are both active in wound healing, CGRP in the earlyphase and SP later. Reports show high density of SP and CGRP inpsoriasis skin, see e.g. Jiang et al. Int. J. Dermatol. 1998,37,572-574.

The substance P antagonist Spantide inhibits immediate and delayed typecutaneous hypersensitivity (DTH) reaction. This could be mediatedthrough CGRP as it is known that CGRP suppresses DTH, thus SP might actas a regulator for CGRP. (Wallengren J. Br. J. Dennatol., 1991, 124(4):324-8)

Substance P regulates the vasodilator activity of CGRP. Experiments inanimals revealed that this phenomenon is dependent on proteases frommast cells. (Brain S.D.; Williams, T.J. “Substance P regulates thevasodilator activity of CORP” Nature 1988 335(6185), 73-5). Theseexperiments showed that SP converts the long lasting vasodilatationinduced by CGRP into a transient response when these neuropeptides wereinjected into human skin. A subsequent study (J. Geronol.: Biol.Sciences 1996; Vol. 51A, No, B354-B361) used a “blister model in the rathind footpad” to demonstrate the ability of SP to terminate an existingvasodilator response to CGRP. The results are seen as not onlyconfirming that combined administration of SP and CGRP in human skin canlimit the vasodilator activity of CGRP, but also that a modulatorinhibitory effect exerted by SP on the vasodilator activity isdose-dependent. This statement could indicate that SP changes inpsoriasis are mainly of regulatory (secondary) nature.

Reports by Haukkarinen et al. (Haukkarinen et al. Journal of Pathology,(1996) 180, 200-205) describe studies of contact values between sensorynerves containing SP, CGRP, and VIP, and mast cells containing activetryptase and inactive chymase. The contact values of SP and CGRP withmast cells are increased in psoriatic lesions, whereas contact valuesfor VIP are decreased. Tryptase effectively cleaves CGRP as well as VIPbut not SP, whereas chymase cleaves SP. This points to a controllingmechanism in psoriasis acting to increasing cleavage of CGRP but not SP,i.e. active tryptase is increased in order to try to down-regulate CGRP,but active chymase is not increased.

In psoriasis, reduced tryptase activity may be the key step inincreasing CGRP activity. This is possibly because a specific step indown-regulation (negative feedback) of CGRP is missing, because CGRP8-37 is not being produced sufficiently. This modified peptide is ahigh-affinity antagonist to the CGRP receptor, as discussed above. If aspecific tryptase in psoriasis is not correctly built and dysfunctional,it can have substantial influence on CPGRP activity. Several mutationsin genes coding for tryptase can be responsible for this. Differingseverity of psoriasis can be explained by different mutations in thespecific tryptase. Thus, if this is the case, psoriasis can be explainedby an alteration in one enzyme system, and possibly just by alterationin a single amino acid for any given subtype of psoriasis, in the enzymetryptase. Certain observations support this notion, for example, smokingis known to increase likelihood of psoriasis, and smoking is also knownto cause defects in tryptase in lungs. This would, however, not changethe effect of the present invention, that by blocking CGRP, psoriasismay be treated or prevented. This hypothesis could be readily verifiedby screening tryptase (or the gene coding for tryptase) from psoriasispatients and control groups to identify possible gene defects.

Several other factors point to CGRP being a much more likely mediator inpsoriasis than SP. CGRP does not induce itch but SP does, and itch ismost often not a symptom associated with psoriasis; CGRP does notproduce weal and flare as much as SP, and SP is very active inconducting pain and burning sensation, neither of which are normallysymptoms of psoriasis. CGRP however produces prolonged erythema, whichis associated with psoriasis, but SP does not

Guttae psoriasis is often seen following streptococcal infection.Several groups of streptococci can induce this. These bacteria have incommon that they all produce exotoxin C, a pyrotoxin that inducesvasodilatation when injected into the skin. This was used in the past asa diagnostic test of streptococcal infection known as the Dicks test.Experimental work from Beijing Medical University has shown that ratsthat are given endotoxin have increased level of CGRP in plasma (Tang etal. Sheng Li Xue Bao 1997 Apr,49(2): 160-6 (Medline abstract PMID:981285 1)). CGRP is released from sensory neurons and also is thetranscription of CGRP mRNA and synthesis of CGRP, in sensory neuronsincreased during the development of endotoxicosis in the rat. Repeatedinjections of endotoxin from staphylococcus induced hyperkeratosis.inimmunodeficiency mice. The onset of psoriasis in the wake ofstreptococcal infection can thus be-explained by an increase in CGRP.

All the aforementioned facts and described observations stronglyindicate that CGRP is a key mediator in psoriasis, which hassubsequently inspired the current invention that relates to methods oftreatment for psoriasis based on the use of specific CGRP antagonists.

Several compounds have been found to selectively inhibit the CGRPreceptor, such as small molecular non-peptide compounds, peptides andantibodies. Such active CGR-P antagonists are expected to be useful inthe treatment of a variety of disease states that are mediated-by CGRP.Diseases that such treatment has been suggested for include headaches,esp. migraines; NIDDM; neurogenic inflammation; cardiovasculardisorders; chronic inflammation, pain, endotoxic shock; arthritis;allergic rhinitis; allergic contact dermatitis; inflammatory skinconditions; and asthma. Such compounds however, have not to my knowledgebeen suggested for treatment of psoriasis.

Compounds disclosed in the prior art found to be useful as antagonistsof CGRP include 4-sulfinyl benzamide compounds (WO 98/56779),3,4-dinitrobenzamide compounds (WO 98/09630), a group of modified aminoacids (WO 00/55154), and benzamidazolinyl piperaditie compounds (WO00/18764).

Antibodies against CGRP have also been described, and inactivederivatives of CGRP, e.g. CGRP 8-37 which differs from normal CGRP inthat it lacks 8 N-terminal amino acids. US 5,935,586 describes the useof CGRP antagonists in therapeutic/cosmetic compositions for treatingdiseases of the skin, in particular, lichens, prurigos, pruriginoustoxidermas and severe pruritus. US 5,932,215 describes similar use fortreating skin redness, rosacea and discrete erythema.

Increased CGRP Activity at the Active Edge of a Psoriatic Lesion

Example 11 describes measuring CGRP using ELISA technique. Example 13,which differs from Example 11, describes detecting CGRP activity usingimmunohistochemical methods, specifically immunohistochemistry ofneuropeptides at an active edge. An active edge of a psoriatic lesion isdefined as the area of a psoriasis lesion, as seen in FIG. 8 , wherethere is significantly increased blood flow as measured by laser Dopplerflownietry. The active edge also shows early histological psoriasischanges. Example 13 confirms that CGRP activity is increased in normallooking skin outside the visible psoriatic lesion. This supports CGRPactivity being responsible for psoriasis, enabling more effectivetreatment by applying CGRP antagonist(s) to normal looking skin outsidethe lesion, where access to the intradermal layers is easier thanthrough the fully thickened scaly lesion. This demonstrates that thearea outside the visible psoriatic lesion, the so called pre-psoriaticrim, is the most active source of CGRP and thus will be effected whentreating with a CGR-P antagonist.

Pre-Psoriatic Rim Treatment of Psoriasis and Local Neural Transport

Determining that the pre-psoriatic rim has elevated CGRP activity isinformative, but insufficient to predict that successful application ofa medicament to the pre-psoriatic rim will be sufficient to affect,i.e., to treat, the whole lesion. The inventor’s successful treatment bypre-psoriatic rim application of a medicament to treat psoriasis wasexplained by observation of interadermal pressurized air canals thatfacilitate delivery from the pre-psoriatic rim area to the skinunderlying the lesion where the pathology is most severe.

Drugs, neural components such as neuropeptides, and hormones, e.g.adrenaline, CGRP, Substance-P, are rapidly transported from one locationto another through channels in the deep dermis. This can be seen whenlidocaine with adrenaline, for local anesthesia, is injected into theskin, e.g., making the spread of vasoconstriction occur in only fewminutes from the sole to the ankle (FIG. 7 ). This transport systemcollapses because of the pressure drop when a skin biopsy is taken,making it difficult to observe as it will become almostindistinguishable from adjacent layers when it has been depressurized.

The most used model to measure drug penetration uses dead skin (Franzcells) and according to the theory, this system does not representnormal function skin. Why drugs or other components are more easily ableto treat the psoriasis lesion via normal skin around the lesion isbecause this system is under the lesion and can be reached more easilyfrom the sides. Psoriasis affects the vessels in the surface and theepidermis; the inflammation is also mostly located in that area,assuming the transport system lies underneath the superficial dermis. Itis very difficult to reach the deep dermis going through thick, scaly,and hyperperfused skin. This depth can likely be reached via normal hairfollicles around psoriasis lesions.

Psoriasis is a complex, multifactorial, lifelong disease of unknownetiology. The two main histological factors of psoriasis are epidermalhyperplasia and inflammatory cell infiltrates in the dermis (Nickoloffand Nestle. Recent insights into the immunopathogenesis of psoriasisprovide new therapeutic opportunities. J Clin Invest, 113(12): 1664- 1675, 2004).

Until the 1980s the primary pathology of psoriasis was considered to beepidermal hyperplasia. Studies over the last decades have on thecontrary indicated that psoriasis is mediated by immunologicalmechanisms. As a result the T- cell theory has been proposed, whichimplies that psoriasis is a disorder of abnormal keratinocyteproliferation caused by activated T-lymphocytes (Christophers, Theimmunopathology of psoriasis. Int Arch Allergy Immunol, 110(3): 199-206,1996). This role of T-cells was first suggested in 1976 after theobservation that psoriasis lesions cleared on cyclosporine treatment(Krueger et al. Inflammatory and immune cell function in psoriasis: II.monocyte function, lymphokine production. J Invest Dermatol, 71(3):195-201, 1978).

The concept of cutaneous neuroimmunology in psoriasis is relativelyrecent. Farber et al. were the first to propose a possible role forneuropeptides in the pathogenesis of psoriasis in 1986 (Farber et al.Stress, symmetry, and psoriasis: possible role of neuropeptides. J AmAcad Dermatol, 14(2 Pt 1):305-311, 1986). Subsequently otherinvestigators observed up-regulation of various neuropeptides inpsoriasis lesions (Naukkarinen et al. Quantitative analysis of contactsites between mast cells and sensory nerves in cutaneous psoriasis andlichen plantis based on a histochemical double staining technique. ArchDermatol Res, 283(7):433-437, 1991; Naukkarinen et al. Quantification ofcutaneous sensory nerves and their substance p content in psoriasis. JInvest Dermatol, 92(1): 126-129, 1989, Abstracts for the 1992 AnnualMeeting of the European Society for Dermatological Research. London,April 4-7, 1992, J Invest Dermatol, 98(4):503-546, 1992), however, theopposite has also been reported (Pincelli et al. Substance p isdiminished and vasoactive intestinal peptide is augmented in psoriaticlesions and these peptides exert disparate effects on the proliferationof cultured human keratinocytes.J Invest Dermatol, 98(4):421-427, 1992).

Neuropeptides and their receptors have been detected in normal humanskin and adjacent epithelial tissues. In the skin, neuropeptides areinvolved in sensory innervation, secretory glands, epidermal growth,regulation of blood flow, and immune cell trafficking. Neuropeptides areimportant in wound healing and tissue repair (Wollina, The effect ofneuropeptides on wound healing in vitro and in vivo, Hautarzt,43(10):616-620, 1992).

Large clinical studies have demonstrated that stress plays an importantrole in the onset or exacerbation of psoriasis (Park and Youn. Factorsinfluencing psoriasis: an analysis based upon the extent of involvementand clinical type. J Dermatol, 25(2):97-102, 1998). Symmetry of lesionsand the well-documented Koebner’s phenomenon where psoriasis appears atthe point of injury are among the cardinal clinical features ofpsoriasis. A study showing psoriasis resolving on a knee after surgerywith sensory loss due to nerve damage, suggests that nerves orneurotransmitters might initiate the psoriasis lesion (Farber et al. Therole of cutaneous sensory nerves in the maintenance of psoriasis. Int JDermatol, 29(6):418-420, 1990). Besides theses clinical observations,histological and electron microscopic studies have shown an acceleratedturnover of neural elements and denser innervation in mature psoriaticlesions (Weddell et al., Psoriatic Skin, Arch Dermatol, 91:252-266,1965). In addition, psoriasis has been linked to the early wound healingprocess both histologically and through the Koebner’s phenomena. (Fosteret al. Calcitonin gene-related peptide is chemotactic for human tlymphocytes. Ann N Y Acad Sci, 657:397-404, 1992).

The neuropeptide calcitonin gene-related peptide (CGRP) is a 37 aminoacid peptide. CGRP acts by stimulating specific CGRP receptors. CGRP isthe most prominent neuropeptide in the skin and is also found in othertissues, e.g. bone and joints. CGRP stimulates keratinocyte, i.e.,epidermal cell, proliferation (Takahashi et al. Direct effects ofcutaneous neuropeptides on adenylyl cyclase activity and proliferationin a keratinocyte cell line: stimulation of cyclic AMP formation by CGRPand VIP/PHM, and inhibition by NPY through g protein-coupled receptors.J Invest Dermatol, 101(5):646-651, 1993) but does not cause irritationor itching (Weidner et al., Acute effects of substance p and calcitoningene-related peptide in human skin- a microdialysis study. J InvestDermatol, 115(6):1015-1020, 2000). CGRP is the most potent vasodilatingcompound known and it is chemotactic and mitogenic for T-cells andneutrophils (Foster et al. Calcitonin gene-related peptide ischemotactic for human t lymphocytes. Ann N Y Acad Sci, 657:397-404,1992; Cuesta et al. Substance p and calcitonin gene-related peptideincrease IL-1 beta, IL-6 and TNF alpha secretion from human peripheralblood mononuclear cells. Neurochem Int, 40(4):301-306, 2002). CGRPincreases TNF-alpha secretion from mast cells and TNF-alpha canstimulate CGR-P secretion from ganglion neurons (Bowen et al. Tumornecrosis factor-alpha stimulation of calcitonin gene-related peptideexpression and secretion from rat trigeminal ganglion neurons. JNeurochem, 96(1):65-77, 2006). CGRP increases various interleukins suchas IL1, IL6, and U.S. These mediators are secreted from various celltypes like keratinocytes, neutrophils, and lymphocytes (He et al.,Calcitonin gene-related peptide induces chemokine interleukine-8synthesis in human monocytes; Yi and Zhi, 82(2):131-134, 2002; Foster etal. Calcitonin gene-related peptide is chemotactic for human tlymphocytes. Ann N Y Acad Sci, 657:397-404, 1992; Cuesta et al.Substance p and calcitonin gene-related peptide increase IL-1 beta,IL-6, and TNF alpha secretion from human peripheral blood mononuclearcells. Neurochem Int, 40(4):301-306, 2002). CGRP directly stimulatesstem cells in the skin (Dong et al., Calcitonin gene-related peptideregulates the growth of epidermal stem cells in vitro. Peptides, 31(10):1860-1865, 2010). CGRP is a strong inhibitor of Langerhans cells(antigen presenting cells) CGRP is an active neuropeptide early in theskin wound healing process (Onuoha and Alpar, Levels of vasodilators(SJ), CGRP) and vasoconstrictor (NPY) peptides in early human burns. EurJ Clin Invest, 31(3):253-257, 2001). UV irradiation causes reduction inthe number of CGRP-immunoreactive nerve fibers in the dermis accordingto study investigating inflammatory process in normal skin (Wallengrenand Sundler. Phototherapy reduces the number of epi-dermal andCGRP-positive dermal nerve fibres. Acta Derm Venereol, 84(2):111-115,2004).

In 1989 Hull et al discovered a growth pattern of psoriasis lesions bydetecting an edge of increased blood flow. They used Laser Dopplerflowmeter to track increased blood perfusion. This increased blood flowwas the growing edge of the psoriasis lesions. By this observation theyshowed that it was possible to locate areas where very early psoriasischanges were present, days or even weeks before they could be seen bythe naked eye (Hull et al. Active and inactive edges of psoriaticplaques: identification by tracing and investigation by laser ---doppler flowmetry and immunocytochemical techniques. J Invest Dermatol,92(6):782-785, 1989).

The hypothesis of the present invention suggests that overrepresentationof calcitonin gene related peptide (CGRP) is responsible for most of thepathological phenomena of psoriasis like hyperproliferation, increasednumber of T-cells, increased blood flow, and localization of lesions. Itcan also explain the therapeutic effect of sunlight, and the negativeeffect of streptococcal infection on psoriasis. Alopecia areata (AA) isa functional hair disease where a lack of CGRP seems to be a causingfactor. An inverse relationship between AA and psoriasis has beenobserved and is described herein. CGRP can be a common factor in bothdiseases, as it is involved in the use of papillary cells for woundhealing and through that route can activate hair follicles in the woundhealing process. It is known that psoriasis is a disease connected tothe early wound healing process. The observations described hereinshowing hexagonal structure of psoriasis lesions strongly suggests thatthe disease involves neural units of sensory innervation. In conclusion,it is a novel hypothesis of the Inventor set forth and supported hereinthat psoriasis is a disease of neural origin and CGRP is likely to be akey mediator of the disease. According to this hypothesis, it is theregulation of CGRP that is not functioning properly in psoriasis, andconsequently, regulation of CGRP by use of a CGRP antagonistic compoundis a way of controlling psoriasis.

The present invention describes a novel method for the treatment andprevention of psoriasis by modulating the concentration of CGRP in thebody, especially in the skin, e.g., by the use of CGRP antagonists. Theinvention is supported by the novel observations and descriptions hereinthat explain psoriasis as a disease of neurological origin for whichCGRP s a key mediator.

The invention is based on the notion that by changing the level of CGRP,at least in the psoriatic, lesions, such as by blocking the activity ofCGRP, the disease can be treated and/or prevented. This may be effectedby the administration of CGRPantagonist compounds, or by administeringtryptase or other compounds affecting the level of CGRP.

In one embodiment, an inventive composition such as a CGRP antagonist istopically administered to the pre-psoriatic rim, the area outside thevisible psoriatic lesion. This method of administration is furtherstrengthened with research data showing increased CGRP activity at thepre-psoriatic rim of a psoriasis lesion. The pre-psoriatic rim is in anormal looking skin outside of the lesion and is confirmed by increasedblood flow measured using laser Doppler technology.

DETAILED DESCRIPTION

As mentioned, the current invention relates to methods for treating,remedying or preventing psoriasis by the use of CGRP antagonistcompounds. To date it has not been envisaged to treat psoriasis withCGRP antagonists. Accordingly, the present invention features the use ofat least one CGRP antagonist compound for the treatment of psoriasis.

CGRP antagonist in this context represents any molecule, whether organicor inorganic, which is capable of reducing the level of active CGRP,e.g., by effecting inhibition of the receptor binding of CGRP or ofeffecting inhibition of the synthesis and/or release of CGRP by nervefibers, or enhancing the breakdown of active CGRP. Thus tryptase activepolypeptides falls within this category as defined herein as they canaffect the level of CGRP by cleavage of the peptide, as well ascompounds stabilizing tryptase, such as heparin. As mentioned above,many compounds have been recently developed that fulfill these criteriaand thus are useful in the current invention.

Treatment in this context indicates any form of therapy that cures orrelieves at least partially the symptoms of the disease, for at least aperiod of time, remedying the disease indicates herein full or partialrelief of psoriasis symptoms.

Microdialysis is a method for tissue fluid sampling. It has been usedboth in the skin and other tissues.

Laser-Doppler flow measurement is a technique for measuring localizedsuperficial blood flow in the skin.

In a first aspect, the invention provides a method of treating psoriasisin a subject comprising administering to the subject a therapeuticallyeffective dose of at least one CGRP antagonist compound in apharmaceutically acceptable formulation. A therapeutically effectivedose will depend on the particular compound selected but is typically inthe range of about 0.00001% to. 5% of the total weight of apharmaceutical composition being used for said treatment, preferably inthe range of about 0.0001% to 2.5 % of weight, such as in the range of0.001 to 1% of weight, or in the range of 0.001 to 0, 1% of weight.

A suitable pharmaceutically acceptable formulation may be formulatedaccording to conventional pharmaceutical methods, depending on thecompound being selected and the intended route of administration, asdiscussed further below.

The method according to the invention includes both systemic and/orlocal treatment. Accordingly, the compositions for use according to theinvention may be administered orally, nasally, rectally, pulmonary,buccally or via subcutaneous: intravenous or intramuscular injection inorder to reach the lesions from a distal administration, or byadministering the composition locally, such as topically, dermally,intradermal or subcutaneously, or via dermal or subcutaneous infusionsuch as through microdialysis. However, presently preferred embodimentscomprise topical administration. In one embodiment, the method comprisesadministration to the pre-psoriatic rim. As can be seen in Example 13,this method of applying a medicament to the pre-psoriatic rim is basedon ground breaking research done by the Applicant. The researchillustrates that the psoriatic activity is occurring outside the lesion,and more specifically at the pre-psoriatic rim in agreement with Example11, where the CGRP activity is found to be increased. These results showthat treatment at the active source of CGRP is most likely to besuccessful in comparison to direct application to the lesion itself.

It will thus be readily understood from the description herein, that theinvention provides in a related aspect, the use of a CGRPantagonistcompound for the manufacture of a medicament for treating, remedying orpreventing psoriasis in a subject in need thereof. Such medicaments arepreferably such compositions as are disclosed herein.

However, in another aspect, the invention provides a method to reducehair growth by the application of a CGRP antagonist compound such asdefined above. This aspect stems from the novel theory that CGRPregulates the hair growth cycle, as discussed above. In preferredembodiments of the invention, these methods comprise the topical ordermal application of medicaments such as a cream, ointment, gel, paste,iontopophoresis system, liquid or lotion, to the area where hair growthreducing effect is wanted.

The topical formulations according to the invention comprise an activeingredient together with one or more pharmaceutically acceptable carrierand/or excipient compounds and optionally one or more therapeuticallyactive ingredient.

Formulations suitable for topical administration may be formulated intoany pharmaceutical form normally employed for such an application, theseinclude liquid or semi-liquid preparations including lotions, creams,pastes, ointments, liposomes, gels, such as for iontopophoresis,suspensions and emulsions, including oil/water (w/o), w/o, o/w/o, w/o/wemulsions or microemulsions. They may suitably be obtained by mixing theactive ingredient in finely-divided or powdered form, alone or insolution or suspension in an aqueous or non-aqueous fluid, with the aidof suitable machinery, with a hydrophobic or hydrophilic basis. Thebasis may comprise hydrocarbons such as hard, soft or liquid paraffin,glycerol, waxes (e.g., beeswax, carnauba wax), metallic soap, amucilage, an oil of natural origin such as corn, almond, castor, orolive oil, mineral oils, animal oils (perhydroxysqualene); or a fattyacid such as stearic or oleic together with an alcohol such as ethanol,isopropanol, and propylene glycol. The formulation may include anysuitable surface active agent such as an anionic, cationic, or non-ionicsurfactant such as sorbitan esters or polyoxyethylene derivativesthereof. Suspending agents such as natural gums; cellulose derivativesor inorganic materials such as silicaceous silicas may also be included.The formulations may additionally comprise absorbtion promoters,stabilizers, e.g. protein stabilizing agents, known in the art.

Known CGRP antagonist compounds which are useful in the currentinvention include 4-sulfinyl benzamide compounds such as those disclosedin WO 98/56779, 3,4-dinitrobenzamide compounds such as those disclosedin WO 98/09630, benzamidazollnyl piparadine compounds such as disclosedin WO 00/18764, CGRP derivatives including CGRP 8-37, having thesequence VTHRLAGLLSRSGGMVKSNFVPTNVGSKAF (SEQ ID NO:1) orVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF (SEQ ID NO: 2), and anti-CGRP antibodies.An interesting compound described in the art a non-peptide moleculeproduced by Boehringer Ingelheim, termed BIBN4096BS (see, Wu et al.,Biochem. Soc. Trans. 2002, Aug. 30(4): 468-473).

Compounds that are believed to have a CGRP antagonist activity and thusbeing candidate compounds for use according to the present inventioninclude:

-   (±)-4-[(2-chlorophenyl)sulfinyl]-N-methyl-N-(2-methylphenyl)-3-nitrobenzarnide;-   (+)-4-[(2-chlorophenypsulfinyl]-N-methyl-N-(2-methylphenyl)-3-nitrobenzamide;-   (-)-4-[(2-chlorophenyl)sulfinyl]-N-methyl-N-(2-methylpheny    l)-3-nitrobenzamide;-   (±)-4-[(4-chlorophenyl)sulfinyl]-N-methyl-N-(2-methylphenyl)-3-nitrobenzamide;-   (±)-N-methyl-N-(2-methylphenyl)-44(1-oxido-2-pyridinyl)sulfinyl]-3-nitrobenzamide;-   (±)-N-methyl-N-(2-methylphenyl)-3-nitro-4-(2-thiazolylsulfinyl)benzamide;-   (±)-N-methyl-N-(2-methylphenyl)-4-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfinyl]-3-nitrobenzamide;-   N-[3-[(diethylamino)carbonyl]propyl]-N-(-2ethylphenyl)-3-nitro-4-(2-thiazolylsulfinyl)benzamide;-   1-[4-amino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]    methylsulfonyliminomethy1]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine;-   1-[4-am in    o-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]    cyanoiminomethyli-D-phenyialanyl]-4-(1-piperidinyl)-piperidine;-   1-[4    amino-3,5-dibromo-N-H4-(3,4-dihydro-2(1H)-oxoquinazolin-3Lyl)-1-piperidinyl]    phenylsulfonyliminomethyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperil-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyllcyanoinninomethyl    J-D-tyrosyl]-4-(1-piperidinyl)-piperidine;-   1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]    methylsulfonyliminomethyll-D-tyrosyli-L-lysyl]-4-(4-pyridinyl)piperazine;-   1-[N2    -[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-l-piperidinyl]    phenylsulfonyliminomethylj-D-tyrosyll-L-lysyl]-4-(4-pyridinyl)piperazine;-   1-[4-am    ino-3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]    cyanoiminomethyli-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)-piperidine;-   1-[4-bromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinylicyanoiminomethyl]-3,5-dimethyl-D,L-phenylalanyl]-4-(1-piperidinyl)-piperidine;-   1-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)oxoquinazolin-3-yl)-1-piperidinyl]    cyanoinninomethyl-D-tyrosy1]-4-(4-pyridinyl)piperazine;-   1-[4-amino-3,5-dibromo-N4[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]    cyanoiminomethyll-D-phenylalanyl]-4-(4-pyridinyl)piperazine;-   1-[3,5-dibromo-N-H4-(3,4-dihydro-2(1H)-oxoquinazolin-3    -yl)-1-piperidinyl]    cyaiioiminomethyl]-D-tyrosy1]-4-(1-methyl-4-piperidinyl)-piperidine;-   1-[3,5-dibromo-N-[[4-[3,4-dihydro-2(1H)-oxoquinazolin-3-yl]-1-piperidinyl]    cyanoinninomethylFD-tyrosyl]-4-(4-methyl-1-piperazinyl)piperidine;-   144-bromo-N-H4-(3,4-dihydro-2(1H)-oxoquinazolin-3-y1)-1-pipedinyl]cyanoiminomethyl]-3,5-dimethyl-D,L-phenylalanyl]-4-(1-methyl-4-piperidinyl)piperidine;-   144-amino-3,5-dibromo-N-[[441,3-dihydro-4-phenyl-2(2H)-oxoimidazol-1-yll-1-piperidinyl]cyanoiminomethyn-D-phenyl-alanyl1-4-(4-methyl-1-piperazinyl)piperidine;-   1-[4-amino-3,5-dibromo-N-[[4-(2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazep    in-3-yl)-1-piperidinyl]cyanoiminomethyll-D-phenylalany11-4-(4-methyl-1-piperazinyl)piperidine;-   1-[4-amino-3,5-dibromo-N-[[4-(2,4-dihydro-5-pheny1-3(3H)-oxo-1,2,4-triazol-2-yI)-1-piperidinylIcyanoiminomethyll-D-phenylalanyl]-4-(1-piperidinyl)-piperidine;-   1-[4-amino-3,5-dibromo-N-[[4-(2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazep    in7-3=yl);    71-_piperidinyficyanoiminomethyli-D-phenylalanyl]-4-(l-piperidinyl)-piperidine;-   1-[3,5-dibromo-N-[[4-(2,4-dihydro-5-phenyl-3(3H)-oxo-1,2,4-triazol-2-yl)-1-piperidinylicyanolminomethyll-D-tyrosyl]-4-(1-piperidinyl)-piperidine;-   143,5-dibromo-N-R4-(2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-piperidinyl]cyanoiminomethyll-D-tyrosyl]-4-(1-piperidinyl)-piperidine;-   1-[3,5-dibromo-N4[4-(2,4-dihydro-5-phenyl-3(3H)-oxo-1,2,4-triazol-2-yl)-1-piperidinyncyanoiminomethylFD-tyrosyl]-4-(1-methyl-4-piperidinyppiperazine;-   1-[3,5-dibromo-N-[[4-(2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)    -1-piperidinyncyanoiminomethyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyppiperazine;-   1-[4-amino-3,5-dibromo-N4[4-(2,4-dihydro-5-phenyl-3(3H)-oxo-1,2,4-triazol-2-yl)-1-piperidinyl]cyanoiminomethyl]-D-phenylalanyl]-4-(1-methy1-4-piperidinyppiperazine;-   1-[4-amino-3,5-dibromo-N-[[4-(2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-piperidinylicyanoiminomethyl]-D-phenylalanyl]-4-(1-methyl-4-piperidinyppiperazine;-   143,5-dibromo-N-H4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]    cyanoiminomethyl]-4-methyl-D,L-phenylalanyl1-4-(1-methyl-4-piperidinyl)-piperidine;-   1-[3,.5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]    cyanoiminomethyl]-4-methyl-D,L-phenylalany1]-4-(1-piperidinyl)-piperidine;-   1-[3,5-dibromo-N-[[4-(3,4-dihydro-2-(1H)-oxoquinazolin-3-yl)-1-piperidinyl]    cyanoiminomethyl]-4-methyl-D,L-phenylalany1]    -4-(4-pyridinyl)piperazine;-   144-amino-3,5-dibromo-N4[4-11,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-yl]-1-piperidinyl]cyanoiminomethyl]-D-phenylalanyl]-4-(1-piperidinyppiperidine;-   1-[4-amino-3,5-dibromo-N-[[4-(7-methoxy-2,3,4,5-tetrahydro-2(1H)-oxo-1,37benzodiazepin-3-yl)-1-piperidinyl]cyanoiminomethyl]-D-phenylalanyl]-4-(1-piperidinyl)-piperidine,-   144-amino-3,5-dibromo-N-[[4-(5,7-dihydro-6-oxodibenzo[d,f][1,3]-diazepin-5-yl)-1-piperidinyncyanoiminomethyl]-D-phenylalanyl]-4-(1-piperidinyl)-pipendinel-   1-[4-amino-3,5-dibromo-N-[[4-(7-methoxy-2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-piperidinylicyanoiminomethyll-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)piperazine;-   144-amino-3,5-dibromo-N-[[441,3-dihydro-2(2H)-oxo-imidazo[4,5-c]quinolin-3-yl]-1-pipendinyl]cyanoiminonnethyl]-D-phenyialany1]-4-(1-methy1-4-piperidinyppiperazine,-   1-[4-amino-3,5-dibromo-N-[[4-(2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiazep    in-3-yl)-1-piperidinyl]sulfonyli-D-phenylalanyl]-4-(1-methyl-4-piperidinyl)piperazine;-   1-[3,5-dibromo-N-[[4-(7-methoxy-2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiaz    epin-3-yl)-1-piperidinylicyanoiminomethyl]-D-tyrosyl]-4-(1-piperidinyl)piperidine;-   1-[3,5-dibromo-N-[[4-(7-methoxy-2,3,4,5-tetrahydro-2(1H)-oxo-1,3-benzodiaz    epin-3-yl)-1-piperidinyl]cyanoiminomethyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)piperazine;-   1-[3,5-dibromo-N-[[4-[1,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-3-y11-1-piperidinyl]cyanoiminomethyl]-D-tyrosyl]-4-(1-piperidinyl)piperidine;-   143,5-dibrotyio-N-[[441,3)-dihydro-2(2H)-oxoimidazo[4,5-c]quitiolin-3-yl]-1-piperidinyl]cyanoiniinoniethyl]-D-tyrosyl]-4-(1-methyl-4-piperidinyl)piperazine;-   144-amino-3,5-dibronno-N4[4-(7-methoxy-2,3,4,5-tetra-hydro-2(1H)-oxo-1,3-benzodiazepin-3-yl)-1-piperidinyl]cyanoiminomethyl-D-phenylalany1]-4-(4-methyl-1-piperazinyl)-piperidine;-   144-amino-3,5-dibromo-N-11441,3-dihydro-2(2H)-oxoimidazo[4,5-c]quinolin-    3-y1]-1-piperidinylicyanoiminomethylFD-phenylalanyl]-4-(4-methyl-1-piperazinyl)piperidine;

and pharmaceutically acceptable salts thereof.

It is further contemplated that indirect inhibitors of CGRP activity maybe useful according to the invention. These include the capsaicinblocker capzaezine, as CGRP is postulated to be under the influence ofcapsaicin through the vanillin receptor. Other such indirect inhibitorsinclude Histamine H3-receptor agonists such as Imetit which candownregulate CGRP.

In a useful embodiment of the invention, the pharmaceutical compositioncomprising a CGRP antagonist compound is administered for treatment ofpsoriasis in combination with another treatment form, such as UVBtreatment which is performed with standard methods in the art

In another aspect of the invention, a method is provided for identifyinga candidate compound for use in a medicament for treating psoriasis. Themethod comprises-the steps of obtaining a compound suspected of bindingto a CGRP receptor; adding the compound at varying concentrations suchas in the range of about 0.1 µM to 1 mM to samples comprising CGRPreceptors and incubating for a suitable time; adding labeled CGRPpeptide to the incubated samples (e.g., radiolabeled, such as byiodine125, though other labeling methods well known in the art areapplicable as well); determining the binding of the labeled CGRP peptideto the CGRP receptor in said samples with varying concentration of thecandidate compound; and determining the binding. affinity of thecompound to the CGRP receptor; whereby a compound that is determined tobind the CGRP receptor is identified as a candidate compound for use ina medicament for treating psoriasis. An embodiment of the methodaccording to the invention is described in detail in Example 10.

In one embodiment of the method said samples comprise live cells havingsurface bound CGRP receptors. In certain embodiments said samplescomprise cell membrane preparations.

In one embodiment, a method for treating psoriasis comprises topicallyadministering a described composition, e.g. a composition comprising aCGRP antagonist, to an area adjacent but not directly on a psoriaticlesion, i.e., pre-psoriatic rim administration, to treat psoriasis, asExample 12 discloses.

BRIEF DESCRIPTION OF THE DRAWINGS

The patent or application file contains at least one drawing executed incolor. Copies of this patent or patent application publication withcolor drawing(s) will be provided by the Office upon request and paymentof the necessary fee.

FIGS. 1 a and 1 b show images that depict the scalp of a patient withalopecia aerata and psoriasis.

FIGS. 2 a and 2 b show a psoriasis pattern on legs of patients.

FIG. 3 shows psoriasis lesions on a finger.

FIG. 4 is an image showing Herpes zoster lesions.

FIG. 5 shows psoriasis lesions formed after skin injury.

FIGS. 6 a and 6 b show patterns of alopecia aerata on the scalp of apatient.

FIG. 7 shows the spread of vasoconstriction when lidocaine andadrenaline, local anaesthesia, is injected into the skin.

FIG. 8 shows a plaque with the active edge circled on the right shoulderbefore pre-psoriatic rim treatment.

FIG. 9 shows the plaque on the right shoulder with the active edgecircled after pre-psoriatic rim treatment.

FIG. 10 shows the plaque completely cleared with a faint “colored trace”after pre-psoriatic rim treatment.

FIG. 11 shows a laser doppler perfusion image of psoriasis plaque andsurrounding skin; measurement sites are shown in colors, each whichrepresents a certain perfusion interval; circled areas are from normalskin on the opposite side of the psoriasis lesion (1) and pre-psoriaticrim (2) psoriasis plaque edges; the graph shows perfusion statistics ofa line drawn through circle 2.

FIG. 12 shows Ki-67 in active (left) vs inactive (right) psoriasis.

FIG. 13 shows Langerhans Cells (LC) in active(left) vs inactive (right)psoriasis.

FIG. 14 shows F-VIII in active(left) vs inactive (right) psoriasis.

FIG. 15 shows CD-3 in active(left) vs inactive (right) psoriasis.

FIG. 16 shows CGRP 3 in active(left) vs inactive (right) psoriasis.

FIG. 17 shows Ki-67 in an active lesion.

The following examples illustrate embodiments of the inventive method.

EXAMPLE 1 Case Study: Possible Involvement of Neuropeptidergic SensoryNerves in AA

A recent study by R. Rossi et al. (Rossi, R. et al. Neuroreport, 8,1135-1138 1997) indicated that patients with AA have lower basal bloodflow. It was further shown that CGRP and SP (substance P) levels but notVIP (vasoactive intestinal peptide) are decreased in scalp biopsies ofpatients affected by AA. Reaction to stimuli is altered, such that agreater and more prolonged vasodilation in response to intradermal CGRPis observed in alopecic scalp than in controls. This is suggested by theauthors of the study to indicate CGRP receptor hypersensitivity, due toa previous reduction in the amount of the neuropeptide present,

EXAMPLE 2 Clinical Observation of a Patient With AA and Psoriasis

A clinical observation of a Down’s syndrome patient with AA andpsoriasis showed that the patient had AA covering an area from one earto the other through his occipital region. His whole scalp was coveredwith psoriasis except for the area where he had AA (see FIGS. 1 a and 1b ). In those areas the scalp was clinically normal. The patient hadpsoriasis on his elbows and a strong family history of psoriasis.

The observation strongly indicates that there is an inverse relationshipbetween the two diseases, which has to my knowledge not been describedbefore. In conjunction with the results of Example 1 that CGRP levelsare lower in AA areas, this further supports the notion that CGRP is acausative agent in psoriasis.

EXAMPLE 3 Clinical Observation of Psoriasis Patients Treated With UVBTherapy

Patients receiving UVB treatment according to standard clinical practicewere observed and interviewed. It was noticed that several patientsexperienced transient worsening of psoriasis after their first treatmentsessions, in the very first days after initiating treatment, before theybegin to get better. Worsening was defined as flare-up or increased sizeof existing lesions or appearance of new ones.

Out of 95 patients interviewed, 38 said they had experienced worseningof their psoriasis. 21 got new lesions, most often lasting for 1 or 2days. These lesions were often described as small, thin and red macules.17 patients noticed a short worsening period of already existingpsoriasis lesions. These symptoms were noted typically within 24-48hours after first treatment. All, patients, however, benefited from thetreatment, i.e., received overall improvement of psoriasis over a longertime.

I postulate that in the beginning of the treatment, increased CGRP is anormal reaction to UV radiation and heat trauma. (This has been observedexperimentally in rats, see Gillardon et al. Neurosci. Lett. 1991 Apr1;124(2): 144-7) As the stimulus is ongoing, it is conceivablybeneficial for the body to increase the specific defense mechanism anddecrease cell turnover, by down-regulation of CGRP. In such a way therisk of mutation and skin cancer may be reduced. Thus, the increasedCGRP levels in skin during beginning of UVB therapy enhances thepatient’s psoriasis symptoms, before the healing effect of the therapysets in.

EXAMPLE 4 Study of Psoriasis Pattern and Location

Psoriasis lesions on a number of patients have been carefully studied toanalyze patterns of the lesions. A hexagonal pattern can be observed onmany patients, see FIGS. 2-3 . Such pattern has not been describedbefore. It is postulated that the pattern is a representation ofneurological units. The exact structure of the nerve innervations in theskin has never been described in detail.

EXAMPLE 5 Herpes Zoster Pattern

The pattern of Herpes Zoster lesions has been studied. It is noted thatsuch patterns also show hexagonal pattern (FIG. 4 ). Herpes Zoster, aviral nerve infection, has a known neurological connection, andtherefore the fact that hexagonal patterns are observed in both HerpesZoster and psoriasis supports that such patterns are representations ofneurological units.

EXAMPLE 6 Psoriasis Lesions Formed After Skin Injury

A psoriasis patient developed psoriatic lesions where his skin had beenscratched or injured. It is frequently observed that lesions appearwhere the skin has been injured, this is called the Koebner’sphenomenon. I observed that the lesions, showed a fine hexagonal pattern(see FIG. 5 ). It can thus be concluded that whereas the location of the“straight-line” lesions is caused by the injury to the skin, the finerstructure-pattern comprising semi-circles or hexagons, is a strongindication of the disease’s neural connection. It can further beobserved in FIG. 5 that the sizes of the hexagons are interrelated suchas e.g. the broader lines are comprised of hexagons that are comprisedof the smaller hexagonal units of the finer lines. This propagationindicates that neural units of fixed size are activated in psoriasis.This has never been suggested before in the prior art.

EXAMPLE 7 Study of Alopecia Areata Pattern

FIGS. 6 a and 6 b of the scalp of a patient with Alopecia areata (AA)reveals that Alopecia spots display non-circular forms resemblinghexagonal shape. In light of the discussion herein regarding therelationship between AA and psoriasis, the indication that -A-A, alsoshows patterns indicative of neural factors further support the notionof psoriasis being a neurological disorder.

EXAMPLE 8 Case Study. Topical Immunotherapy for Alopecia Areata

Ot-ecchia et al. (Orecchia, G. et al. Dermatologica 1990, 180, 57-59)describe treatment of AA with SABDE (squaric acid dibutylester), atopical sensitizer. A patient who received the treatment developedpsoriasis at the same spot where he got hair regrowth. Hairs on thepsoriatic plaques were the last to fall off when the diseaseprogressively worsened after treatment, to Alopecia Universalis.

As discussed in the detailed description, to activate keratinocytes fromhair follicles which act as reserve cells, CGR-P can turn the hair inresting phase (telogen phase) into active phase (anagen phase). When thebody is exposed to antigen in very small quantities (as topicalimmunotherapy) CGRP is released to stop the process of delayed typehypersensitivity (DTH) to evolve. I believe that is the reason why SABDEand DPCP are effective in treatment of Alopecia Aerata. This mechanisminvolving CGRP as a down-regulator of DTH and actor in early woundhealing which is able to turn hair follicles from telogen to anagenphase explains why there is an inverse relationship between psoriasisand AA, as demonstrated in the Example 1.

EXAMPLE 9 Lotion for Treating Psoriasis

A lotion for treatment and/or prevention of psoriasis by topicaladministration may be prepared as follows:

A suitable compound is selected, from those disclosed in the descriptionor a compound identified with the method of Example 10 percent lotion isprepared as follows: about 0.1 to 0.5 g of the compound is dissolved inethanol (6 ml), and the solution is admixed with a water-in-oil lotion(95 g) prepared from mineral oil, cottonseed oil, isopropyl palmitateand water with a surfactant such as sorbitan sesquioleate. Theingredients in the water-in-oil lotion are present for example in10:10:5:70:5 parts by weight respectively.

EXAMPLE 10 Screening for Antagonistic Compounds

A method is described in WO 98/56779 to screen for compounds that hinderthe CGRP receptor from binding CGRP. Thus, the method will identifycompounds that are likely to be useful for the current invention.

Briefly, the selected test compounds are assayed for the inhibition of[¹²⁵1] CGRP (from Amersham, Chicago, IL). SK-N--MC cells (American TypeCulture Collection, Rockville, MD) are grown in Minimum Essential Medium(“MEM”) containing fetal calf serum (10%). Cells are grown in T-150flasks or Costar® multiwell plates and maintained at 37° C. in a 90%humidified incubator with an atmosphere of 5% CO₂ and 95% air.

The cells are homogenized in 5 mM Tris-HCI pH 7:4, 10 mM Na-EDTA and thehomogenate centrifuged at 48,000 g for 20 min at 4° C. The pellet isre-suspended in 20 mL Na-HEPES pH 7.4, 10 mM MgCl2 and recentrifuged.The membrane pellets are re-suspended in the same buffer and storedfrozen at -70° C. The protein concentration is measured by the PierceBCA method using BSA (Bovine serum albumin) as a standard.

The [¹²⁵1]CGRP receptor binding assay is performed using a buffer of20.mM Na-HEPES pH 7.4, 10 mM MgC1₂, 0.05% BSA and 0.1 mg/mL bacitracin.The membranes (50 pg/mL) are incubated with various concentrations (suchas in the range of about 1 pM and 1 mM) of the test compounds and 40 pM[¹²⁵1]CGRP in a total volume of 500 pL for 60 min at 25° C. The reactionis terminated by addition of 2 mL ice-cold 0.9% NaCl, followed by rapidfiltration through Skatron Filterinates pre-soaked in 0.5%polyethylenimine (PEI). The filters are rinsed twice with 2 mL of cold0.9% NaCl and the radioactivity counted in a gamma counter. The bindingdata is analyzed with conventional ligand-binding calculations andprograms, such as the LIGAND 2 program.

EXAMPLE 11 Measurement of CGRP in Edges Surrounding Psoriasis Lesions

Laser Doppler blood flow measurement was used to measure blood flow innormal skin surrounding psoriasis lesions to determine the location ofthe active edge of psoriasis lesions. It is known that psoriasis lesionsgrow directionally, i.e., have a growing or active edge (see, Cunliff etal. J. Invest Dermatol. 1989, 92(6):782-5). CGRP levels were measured inboth the active edge and the inactive (opposite) edge in two subjectshaving psoriasis lesions. Initial results indicate that CGRP levels areincreased in the pre-psoriatic rim as compared to the normal skin on theopposite side outside the lesion. The experiment was conducted by theuse of microdialysis equipment for tissue fluid sampling with a 15 kDacutoff probe; both the active and inactive edge were sampled for a totalof 165 min. each sample to obtain a volume of 165 pL in each sample.Neuropeptide CGRP concentration was measured with ELISA. Tissue biopsiesfrom the sampled skin locations were taken after the tissue fluidsampling. At the active edge increased blood flow was observed indicatedby increased capillary blood vessels indicated by increased number ofcapillary loops in the papillary dermis, which also were dilated. Noepidermal hyperplasia or T-cell activation were found.

The results strongly indicate that increased concentration in CGRP levelin the skin is a very early event in the development of psoriasis. Thissupports that failure in regulating the CGRP level (i.e. an enhancedCGRP level) could be a causative factor in the psoriasis disease.

EXAMPLE 12 Pre-Psoriatic Rim Administration and Treatment of Psoriasis

A selected compound as described herein or identified with the method ofExample 10 is prepared as by dissolving about 0.1 to 0.5 g of thecompound in ethanol (6 ml), then the solution is admixed with awater-in-oil lotion (95 g) prepared from mineral oil, cottonseed oil,isopropyl palmitate and water with a surfactant such as sorbitansesquioleate. The ingredients in the water-in-oil lotion are present,e.g., in 10:10:5:70:5 parts by weight respectively. In one embodiment,0.10 g of the compound is dissolved in 80.0 g aqueous 20.0 mM aceticacid buffer pH 4.0, containing 4.0 g of glycerol, 7. 0 g of sorbitol and0.1 g of methylparaoxybenzoate. In one embodiment, the ingredients inthe aqueous phase are present in 84.875:8.75:6.25:0.125 parts by weightrespectively. In one embodiment, the oil phase is 20.0 g and consists of0.5 g of polysorbat 80, 6.0 g of cetosterayl alcohol, 6.0 g of paraffinoil and 7.5 g of glycerolmonostearate 40-50 (2.5:30:30:37.5 parts byweight respectively). In one embodiment, the oil phase is heated up to70° C. and mixed in an emulsion machine for 2 minutes with 65° C.aqueous phase to prepare an oil-in-water emulsion and cooled to roomtemperature under manual stirring. In one embodiment, 0.10 g of thecompound is dissolved in 99.0 g aqueous 20.0 mM acetic acid buffer pH4.0, containing 0.1 g of methylparaoxybenzoate. 1.0 g ofHydroxypropylcellulose (Klucel® HF hydroxypropylcellulose) is added tothe solution and stirred until uniform fully hydrated gel forms (30minutes).

In one embodiment, a composition for topical administration was preparedusing the peptide CGRP8-37 in a topical formulation at 20 µg/g. Theeffective range of the peptide in the composition can be between 0.00001µg/g to 1 g/g, depending on formulation and measured penetrationparameters.

The described composition was applied to an area at least partiallyaround the psoriatic lesion(s), termed the pre-psoriatic rim, which wasdetermined using well known laser Doppler flowmetry. As shown in FIGS.8-10 , the results demonstrate the lesion first retreating in thedirection of the active edge (FIG. 9 ) and then clearing completely(FIG. 10 ). 10 µg/g of the peptide was applied twice daily for 4 weeks.The composition was purposely not applied directly to the lesion.

Without being held to a single theory, a novel local neural transportmechanism appears to be responsible for the effects observed by thepre-psoriatic rim administration resulting in treatment of psoriasis.Topical steroids are usually applied directly on lesions as is theconvention for most topical treatments. Topical steroid molecules aremuch smaller (<500 Da) then CGRP8-37 (3100 Da) and therefore can moreeasily penetrate thick skin, topical steroids also have a side-effect onnormal skin causing skin atrophy in some cases. That is why, forsteroids and some other topical remedies e.g. tar (being irritating tonormal skin), applying around the lesion is not recommended. Psoriasislesions have a very thick scaly layer and getting large molecularstructures through the skin is problematic. Due to CGRP8-37 molecularsize, direct application is thus not likely to be successful fortreatment. By applying around the lesion the uncompromised dermaltransport layer is used to facilitate the delivery of the CGRP8-37peptide to the deeper layers of the skin and the site of pathology,resulting in overall greater effectiveness and a possibility for lowerdosage and milder side-effects. This low dosage indication has beenobserved by applying doses as low as 1 µg/g of topical formulation withsignificant improvement.

As shown in this example, the described composition was administered toan area around a psoriatic lesion to provide treatment of psoriasis. Inone embodiment, the approximate area around the lesion required forsuccessful pre-psoriatic rim application is around an inch (~2.5 cm),but is adjusted in proportion to the size of the lesion. This does notrequire that the composition is only applied around the lesion(s), asdepending on the pattern of lesions, some of the topical administrationmay be applied to the lesion(s) either inadvertently or advertently.This method of pre-psoriatic rim application is most likely to effectiveon plaque psoriasis, inverse psoriasis and scalp psoriasis. However, thedata demonstrate that administration around the lesion(s), i.e.,pre-psoriatic rim administration, is required, contrary to typical useof topical treatments for psoriasis, which are directed to be applieddirectly to the lesion(s). Not shown are numerous unsuccessfulapplications of CGRP antagonist directly to plaques where the lack ofpenetration due to the thickness of the skin is the most likely reasonfor non-response.

EXAMPLE 13

The active edge of a psoriasis lesion has increased blood flow and themacroscopic normal skin shows microscopic early psoriasis changes. Thisactive edge is identified using laser Doppler flowmetry. Earlierimmunohistochemical studies on neuropeptides (NPs) in psoriasis skinhave shown conflicting results. No defined alterations of specificsubsets of peptidergic fibers have been found. The inventorsdemonstrated, for the first time, that CGRP is increased at thepre-psoriatic rim outside of a psoriasis lesion which later becomesfully psoriatic skin. This information indicates that extralesional,referred to as pre-psoriatic rim, application is the most effective wayof treating psoriasis with a CGRP antagonist. The disclosure supportsthat the source of the increase in CGRP is from outside the lesion, thustreatment should be at this source.

Immunohistochemical studies of neuropeptides (NP) in mature psoriasisskin have shown conflicting results, and no defined changes inneuropeptide have consistently been found (Wallengren et al. Substance pand vasoactive intestinal peptide in bullous and inflammatory skindisease. Acta Derm Vetiereol, 66(1):23-28, 1986; Pincelli et al.Neuropeptides in skin from patients with atopic dermatitis: animmunohistochemical study. Br J Dermatol, 122(6):745-750, 1990, Anand etal. Neuropeptides in skin disease: increased VIII in eczema andpsoriasis but not axillary hyperhidrosis. Br J Dermatol, 124(6):547-549,1991). Apparently normal skin at the growing edge of the psoriasislesion has increased blood flow, identified by laser Doppler flowcytometry; histology samples showed early psoriatic changes (Hull etal., active and inactive edges of psoriatic plaques: identification bytracing and investigation by laser-doppler flowmetry andimmunocytochemical techniques. J Invest Dermatol, 92(6):782-785, 1989).Investigating this growing area gives more distinguishing resultsrevealing the most active neuropeptide that, when identified, could beimportant in pathogenesis of psoriasis.

The presence or absence of selected neuropeptides in early psoriasischanges were evaluated and early histological changes that were presentwere analyzed.

Biopsies were taken from apparently normal skin adjacent to psoriaticlesions, i.e. the pre-psoriatic rim, using non-invasive Laser DopplerPerfusion Imaging (LDPI) technique which was very- successful inlocating early psoriasis changes. Histological markers were used toevaluate neuropeptides, epidermal keratinocyte proliferation, vasculardensity, T-cells, neutrophils, and Langerhans cells.

Biopsies using immunohistochemical methods showed increased calcitoningene-related peptide (CGRP) in eight of eleven biopsies from thepre-psoriatic rim of the psoriasis lesions, compared to the oppositeside. Substance P (SP) and vasoactive intestinal peptide (VIP) showednow such changes.

Blood perfusion, keratinocyte proliferation, and T-cell infiltrationwere increased in very early psoriasis changes where CGRP was alsosignificantly increased. CGRP is a very strong vasodilator, itstimulates keratinocytes growth and is chemotactic for T-cells so may bedirectly involved in psoriasis pathogenesis and could even be theinitiating factor.

Eleven patients with moderate to severe plaque type psoriasis werestudied; three women, eight men, ages 26-65 years (Table 1):

Patient # Age Sex Smoking Current Treatment Age at Onset Genetic DiseaseGrade Biopsy Location 1 26 M - 0 20 + Moderate Back 2 41 M - 0 23 ++Severe Left arm 3 35 F - 0 18 + Severe Left thigh 4 35 F + 0 17 ++Severe Left thigh 5 54 F - MTX/Remicate 7 ++ Moderate Right leg 6 63 F -0 17 ++ Moderate Right leg 7 65 M + 0 58 + Severe Back 8 48 M + UVB 34 +Moderate Left leg 9 47 M + 0 32 ++ Moderate Left leg 10 49 M - UVB 15 +Moderate Left leg 11 65 M - 0 20 ++ Moderate Right thigh

Perfusion images (scans) were made of psoriasis plaques and surroundingskin with a PIM II high-resolution laser Doppler perfusion imager andthe LDPIWin version 2.1 software (Perimed AB, Järfälla Sweden).

Subject-environmental-technical guidelines for reading of patch testswith the laser were followed (Bjarnason et al. Objective non-invasiveassessment of patch tests with the laser doppler perfusion scanningtechnique. Contact Dermatitis, 40(5):251-260, 1999) except for an 8 cmdistance between the aperture of the laser head and tests and lowresolution. Those changes were required because of the advancements inhigh-resolution laser since the guidelines. In addition, a backgroundthreshold of 6.2 V and a scan size of 64×64 mm measurement sites weremade to secure a reasonable skin area surrounding the plaques.

A standard reading speed was used. Perfusion images were analyzed forblood flow and sites were marked for biopsies. Following localanesthesia with lidocaine and adrenaline (20 mg/ml) two 3 mm punchbiopsies were taken from each subject; one sample taken from the edgewith lower blood perfusion (no. 1 (Inactive)) and another from the edgewith higher blood perfusion (no. 2 (Active)).

FIG. 11 shows a typical perfusion scan with the laser. Each measurementsite of the scan was assigned a color representing a certain perfusioninterval. The psoriasis plaque was located in the middle of the scanwhere the perfusion was increased. Punch biopsies were taken in themiddle of the circled areas. Circle no. 1 is from an inactive edge ofthe psoriasis plaque with low perfusion while circle no. 2 is from anactive edge with high perfusion. A line has been drawn through circleno. 2 on the left side of the figure and the line statistics are shownon the graph. The top of the line in the figure on the left side is onthe left of the graph on the right side. The perfusion was higher withinthe circled area in the middle of the graph compared to the surroundingskin.

Skin samples from eleven individuals with psoriasis were obtained afteranalysis with Laser Doppler Perfusion Imaging (LDPI). Samples from fourindividuals were fixed in 10% buffered formaldehyde for 12 hrs andsamples from another seven individuals were frozen instantly in liquidnitrogen. The change after four patients attempted to obtain moresensitivity for the immuno-histochemical markers. All samples wereexamined blindly and independently by two pathologists.

Serial sections were cut and mounted on poly-L-lysine-coated glassslides and immunohistochemical studies were done using the followingantibodies: factor VIII polyclonal antibody (Ab) (Dako), CD-34monoclonal Ab (Novocastra), Ki-67 monoclonal Ab (Novocastra); VIPpolyclonal Ab monoclonal Ab (BD Biosciences); CD-20 monoclonal Ab(Daco); S-100 polyclonal Ab (Daco).

Frozen (Fr.) and formalin fixed, paraffin-embedded (Par) tissues weresectioned onto silane-coated slides and pretreated in accord withmanufacture’s recommendations. Internal positive controls were presenton every slide; appropriate negative controls were also performed foreach specimen. Primary antibodies were incubated at predetermineddilutions. A biotinylated secondary antibody and streptavidin-peroxidasesteps were then performed with the color reaction developed using3,3-diarainobenzidine as substrate. Sections were counterstained withhematoxylin.

Biopsies were examined for neuropeptides, blood vessels, keratinocyteproliferation neutrophilic infiltration, T-cells, and Langerhans cells.Results from sites 1 and 2 were compared using statistical analysis withWilcoxon Signed Ranks Test.

Two independent pathologists analyzed the pathological slides blindedfor site. Their results were compared statistically using Cohen’s KappaStatistic Test.

The deep dermal and superficial nerve plexus was evaluated specificallyfor CGRP staining. The staining pattern was overall relatively faint andranged from an occasional positive nerve fiber (+) to several positivefibers (+++), predominantly in a superficial dermal location.

The dermal deep and superficial nerve plexuses were evaluatedspecifically for substance P (SP) and vasoactive intestinal peptide(VIP) staining. The staining pattern was negative in most cases orshowed an occasional faintly positive nerve fiber (+).

The prominence of the superficial vascular plexus at the papillary-reticular dermal junction was evaluated. Tissue sections were stainedwith F- VIII and CD-34 respectively to highlight the dermal capillaries.A relatively similar staining pattern was observed with both antibodies.The vascular prominence was scored from + to +++ depending on the numberand width of cross-sectioned capillaries in three consecutive papillarydermal regions.

For analysis, a well-oriented field was selected and 150 nuclei werecounted. Positive staining was recorded specifically, noting bothlocation and extent. The degree of staining was expressed as numbers ofpositive cells: + (1-10 cycling cells), ++ (11-20 cycling cells) and +++(> 20 cycling cells).

Dermal papillae capillaries and superficial postcapillary venular plexuswere evaluated for the presence or absence of perivascular lymphocytes.The T- and B-cell phenotypes were identified with CD-3 and CD-20antibodies respectively. The cross-sectioned dermal vessel with the mostdense lymphocytic infiltrate was selected and the density of theinflammatory infiltrate was scored as follows: + (1-10 lymphocytes), ++(10-20 lymphocytes) and +++ (> 20 lymphocytes).

The presence of Langerhans cells within the epidermis was evaluated. Awell-oriented field was selected and 50 nuclei were counted. The numberof positive cells within the field was noted. Histology samples were notavailable for this analysis from all patients.

The presence or absence of neutrophil exocytosis within the stratumcorneum, or stratum spinosum was evaluated as well as neutrophils withinthe perivascular inflammatory infiltrate.

Table 2 shows histological comparison between pre-psoriatic skin (biopsysite 2) and normal skin on the opposite side of the psoriasis lesion(biopsy site 1):

Patient ^(.) Biopsy Site CGRP SP VIP F-VIII Ki=67 T N APC 1 (Par) 12 + + 0 0 0 0 + ++ + ++ 0 ++ 0 0 9 6 2(Par) 1 2 0 +++ + + 0 0 + +++ ++++ + + 0 0 8 3 3(Par) 1 2 0 0 0 0 0 0 + +++ + +++ + ++ 0 0 11 7 4(Par)1 2 0 +++ + + + + + +++ + ++ + +++ 0 0 8 3 5(Fr.) 1 2 + +++ + + 0 0 ++++ + +++ + +++ 0 0 7 4 6(Fr.) 1 2 + + 0 0 0 0 + ++ + +++ + +++ 0 0 9 47(Fr.) 1 2 0 +++ + + 0 0 + ++ + +++ + +++ 0 0 n/a 8(Fr.) 1 2 +++ + + + + + +++ + ++ + + 0 0 6 5 9(Fr.) 1 2 0 ++ + + 0 0 + ++ ++++ + + + 0 0 9 6 10(Fr.) 1 2 0 +++ + + 0 0 + +++ + +++ + ++ 0 0 n/a 11(Fr.) 1 2 0 ++ + + 0 0 + +++ + ++ + +++ 0 0 n/a P value 0.001 nss nss0.003 0.003 Psoriasis Control +++ 0 + 0- + 0 +++ + +++ + +++ + +++ 0 210

Use of laser Doppler permitted identification of areas outside psoriasislesions where histopathology changes of early psoriasis lesions could bedetected. Two opposite sides (poles) of the psoriasis lesions could bedetected with quite different histology.

Biopsies from macroscopic normal looking skin showed either psoriasis inits earliest phase or almost normal morphology. These two areas werecompared in regard to various histochemical and immunohistochemicalmarkers. The active site had increased keratinocyte proliferation (Ki67) in the basal layer compared to the inactive site (p=0.003, FIG. 12).

Epidermis in the active site showed no signs of acanthosis,parakeratosis, or disruption of the basket wave structure of the stratumcorneum (hemotoxylin-eosin stained slides). Keratinocyte morphology wasnormal and the granular layer which often is absent in psoriasis wasstill intact. There were no infiltration of neutrophils in the epidermisor dermis. Langerhans cells (LC) were fewer than in the inactive siteshown by S-100 staining in the active site, and their dendrites appearedshort and sometimes absent (FIG. 13 ). In the dermis, dilated vesselswere prominent in early lesions demonstrated clearly by staining forvonWillebrand factor (p=0.003, FIG. 14 ).

Vascular pattern and keratinocyte proliferation differences between thetwo sides (poles) were seen in all sample pairs (Table 2). Proliferatingkeratinocytes on the active site were seen on some slides in the outerrouth (the outermost layer of the hair follicle which is known tocontain epidermic stem cells) sheet of follicles, indicating involvementof stem cells (FIG. 1 7). T-cell infiltration (CD-3) in the dermis wasdense in all but two biopsies taken from the active site (FIG. 15 ). NoCD-20 positive cells indicating B-lymphocytes were observed.

Substance P (SP) was detected on staining in 8 of 11 samples. Nodifference was observed between the two biopsy sites (Table 2).Vasoactive intestinal peptide (VIP) was detected in both biopsies from 2patients, with equal intensity of staining in both pairs. CGRP wasincreased in 8 of 11 samples taken from the pre-psoriatic rim comparedto the normal skin on the opposite side of the psoriasis lesion(p=0.001, FIG. 16 ). CGRP was often detected around hair follicles (FIG.16 ) and was detected in low intensity in 4 of 11 samples on theinactive site.

The data demonstrate novel very early changes in psoriasis, with specialreference to the neuropeptide CGRP. Skin samples evaluated were takenfrom clinically normal looking skin, showing no acanthosis nor changesin the stratum corneum. CGRP was increased in these early psoriasissamples simultaneously with the hallmarks of psoriasis i.e.vasodilation, keratinocyte proliferation, and T-cell infiltration. CGRPcan initiate all these changes beside being a strong suppressor ofLangerhans cells (APC), indicating CGRP plays a major role in psoriasis.

CGRP was a specific stimulator of T-cell migration into 3D collagen typeI matrices, whereas a number of other neuropeptides and opioids did notinfluence T cell infiltration. CGRP significantly stimulated migrationof non-activated and anti-CD3 activated T-lymphocytes. Virtually allmigrating cells were CD3+ (>96%) and CGRP did not stimulate B-cellmigration (Talme et al., The neuropeptide calcitonin gene-relatedpeptide (CGRP) stimulates t cell migration into collagen matrices. JNeuroimmunol, 196(1-2):60-6, May 2008). The same lymphocyte profile wasseen, indicating a nonspecific T-cell immune response (innate immunity).

Langerhans cells antigen presenting cells (APC) are the central cells inmany models of the T-cell theory even though some studies have shownthem to be reduced in psoriasis. Marked decrease in density ofLangerhans cell population in psoriatic plaques was shown using ATPasehistochemical staining of frozen skin sections (Kierland, Psoriasis:Proceedings of the international symposium-Stanford University 1971).There was marked decrease in the density of the Langerhans cellpopulation in psoriatic plaques, restored after successful treatmentwith methotrexate and Goeckerman Regimen (Archives of Dermatology, 106(1972) 137). The inventors demonstrated that Langerhans cells were notonly decreased but also showed signs of suppression, seen by markedreduction of dendrites. This is the first time these changes were seenas a part of very early psoriasis changes present alongside keratinocyteproliferation and immune cell infiltration.

Immunohistochemical staining in early psoriasis revealed CGRP confinedto nerve endings. CGRP might also originate from other sources. Humanlymphocytes can produce CGRP (Wang et al., Production and secretion ofcalcitonin gene-related peptide from human lymphocytes. J Neuroimmunol,130(1-2): 155-162, 2002; Nickoloff and Nestle. Recent insights into theimmunopathogenesis of psoriasis provide new therapeutic opportunities. JClin Invest, 113(12):1664-1675, 2004). T-cells activated by IL-2 producehigh amount of CGRP (Xing et al., Induction and expression ofbeta-calcitonin gene-related peptide in rat t lymphocytes and itssignificance. J Immunol, 165(8):4359-4366, 2000). Increased CGRPactivity or secretion need not be limited to injured or altered nervefunction, it could be secondary to altered immune response involvingT-cells, or could be a second step in the events of inflammation or thewound healing process for T-cells to continue CGRP production. In theSCID mouse model system, IL-2 is used to activate T-cells before theyare injected into skin grafts. These activated T-cells stimulate apsoriasis phenotype in the grafts (Wrone-Smith and Nickoloff, Dermalinjection of immunocytes induces psoriasis. J Clin Invest, 98(8):1878-1887, 1996; Nickoloff et al. Characterization of a t cell linebearing natural killer receptors and capable of creating psoriasis in aSCID mouse model system. J Dermatol Sci, 24(3):212-225, 2000).

Activated T-cells may in fact produce increased amounts of CGRP.Theories of T-cell activation and nerve dysfunction can be combinedthrough increased CGRP activity. Many possible dysfunctions can lead tothis increased activity. Psoriasis is likely not one disease but severaldiseases sharing a final common pathway. These data are the first todemonstrate increased CGRP in early psoriasis lesions that may be thesole cause of the pathophysiology seen in psoriasis.

The embodiments shown and described in the specification are onlyspecific embodiments of the inventor who is skilled in the art and arenot limiting in any way. Therefore, various changes, modifications, oralterations to those embodiments may be made without departing from thespirit of the invention in the scope of the following claims. Referencescited are expressly incorporated by reference herein in their entirety.

What is claimed is:
 1. A method of treating an inflammatory skin disease mediated by over-expression of a calcitonin gene-related peptidein an individual in need thereof, the method comprising applying to anedge of a lesion associated with the inflammatory skin disease atherapeutically effective dose of an antagonist of a calcitoninreceptor-like receptor.
 2. The method of claim 1, wherein the antagonistof the calcitonin receptor-like receptor is selected from the groupconsisting of 4-sulfinyl benzamide compounds, 3,4-dinitrobenzamidecompounds, benzamidazolinyl piperadine compounds, a calcitoningene-related antagonistic peptide, a derivative of a calcitoningene-related antagonistic peptide, tryptase active polypeptide, ananti-calcitonin gene-related peptide antibody, BIBN4096BS, and atryptase stabilizing compound.
 3. The method of claim 1, wherein theantagonist of the calcitonin receptor-like receptor is a derivative of acalcitonin gene-related peptide.
 4. The method of claim 1, wherein theantagonist of the calcitonin receptor-like receptor is administeredtopically.